Merck Animal Health (known as MSD Animal Health outside the U.S. and Canada) has announced that the FDA has approved NUMELVI, a new treatment for itchy skin in dogs caused by allergies. NUMELVI is the first and only second-generation Janus kinase (JAK) inhibitor for this condition. It will be available at veterinary clinics and hospitals in spring 2026.
Why NUMELVI is needed:
Skin problems are common in dogs and can make up to 20% of the cases veterinarians see. Allergic skin conditions can cause itchiness, pain, and discomfort, which can affect the dog's quality of life and the bond between the dog and its owner.
How NUMELVI works:NUMELVI is a once-a-day treatment that helps reduce itching from the first dose. It works by targeting a specific part of the immune system (JAK1) that causes itching and inflammation in allergic skin conditions. This treatment is safe, effective, and works for dogs as young as six months old.
Executive Statement
According to Christine McKinney, DVM, DACVD and Senior Professional Services Veterinarian, Merck Animal Health, Merck Animal Health is proud to introduce NUMELVI, their latest advancement geared at rapidly controlling pruritus associated with allergic dermatitis, a common condition that causes distress for so many pets and pet owners. With more than 70 years of innovation and commitment to animal health, they are confident that NUMELVI will offer veterinary professionals a groundbreaking, first-of-its-kind solution aimed at improving the health and well-being of dogs as young as six months of age to mature dogs – and ultimately providing peace of mind for the people who care for them.